Barry Frankel
Founder at Sedor Pharmaceuticals LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John A. Sedor | M | 80 |
Sedor Pharmaceuticals LLC
 Sedor Pharmaceuticals LLC Financial ConglomeratesFinance Sedor Pharmaceuticals LLC is a pharmaceutical company that identifies, acquires, and develops acute care pharmaceutical assets for commercial licensing. The private company is based in Paoli, PA, and was founded by John A. Sedor and Barry R. Frankel. The company's lead product, Sesquient, has received FDA approval for the treatment of status epilepticus, and they are preparing to enter phase I development of their second product, Meloxicam for injection solubilized with betadex sulfobutyl ether sodium, for the potential treatment of acute post-surgical pain. Both products were licensed from Ligand Pharmaceuticals. The company is led by Chairman and CEO John Sedor and an experienced team of pharmaceutical professionals. John A. Sedor has been the CEO since incorporation. | 10 years |
| Peter Knight | M | 73 | 6 years | |
| Gary Rubin | M | 68 | 7 years | |
| James L. Bicksler | M | 86 |
Rutgers State University of New Jersey
| 55 years |
| Gary Floyd | M | - |
Sedor Pharmaceuticals LLC
Sedor Pharmaceuticals LLC Financial ConglomeratesFinance Sedor Pharmaceuticals LLC is a pharmaceutical company that identifies, acquires, and develops acute care pharmaceutical assets for commercial licensing. The private company is based in Paoli, PA, and was founded by John A. Sedor and Barry R. Frankel. The company's lead product, Sesquient, has received FDA approval for the treatment of status epilepticus, and they are preparing to enter phase I development of their second product, Meloxicam for injection solubilized with betadex sulfobutyl ether sodium, for the potential treatment of acute post-surgical pain. Both products were licensed from Ligand Pharmaceuticals. The company is led by Chairman and CEO John Sedor and an experienced team of pharmaceutical professionals. John A. Sedor has been the CEO since incorporation. | - |
| Xavier Reveles | M | 55 | 7 years | |
| Vivienne Rebel | M | 59 | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert P. Hickey | M | 78 |
SyntheMed, Inc.
 SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 15 years |
| Rick Franklin | M | 78 |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 11 years |
| Douglas A. Duchak | M | - |
Rutgers State University of New Jersey
| 5 years |
| Helen M. Galt | F | 76 |
Rutgers State University of New Jersey
| 5 years |
| Clifford George Viner | M | - |
University of Pennsylvania
| 6 years |
| George R. Hedges | M | - |
University of Pennsylvania
| 5 years |
| Donald Martin Gilbert | M | - |
University of Pennsylvania
| 6 years |
| Mark T. Coffin | M | - |
University of Pennsylvania
| 4 years |
| Joerg Gruber | M | 63 |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 4 years |
| Michael D. Zisman | M | 75 |
University of Pennsylvania
| 5 years |
| James W. Mortenz | M | - |
University of Pennsylvania
| 3 years |
| Thomas J. Cafferty | M | - |
Rutgers State University of New Jersey
| 7 years |
| Mohsin Meghji | M | 60 | 5 years | |
| Gaston Silva | M | - |
University of Pennsylvania
| 5 years |
| Allan Harvey Cohen | M | 73 |
Rutgers State University of New Jersey
| 5 years |
| Mark L. Friedman | M | 76 |
University of Pennsylvania
| 7 years |
| Vincent A. Cino | M | - |
Rutgers State University of New Jersey
| 10 years |
| Lowell Kwiat | M | 72 |
University of Pennsylvania
| 4 years |
| Kevin G. Doren | M | - |
University of Pennsylvania
| 4 years |
| Ronald J. Solar | M | - |
University of Pennsylvania
| 3 years |
| Paul Scura | M | - |
University of Pennsylvania
| 2 years |
| John Luth | M | - |
University of Pennsylvania
| 2 years |
| Kevin Simpson | M | - |
University of Pennsylvania
| 4 years |
| Alan Beller | M | 74 |
University of Pennsylvania
| 3 years |
| Jack Bader | M | - |
University of Pennsylvania
| 4 years |
| Kenneth H. Landis | M | 73 |
University of Pennsylvania
| 4 years |
| Michael K. Furey | M | 74 |
University of Pennsylvania
| 3 years |
| Douglas Koebler | M | - |
University of Pennsylvania
| 4 years |
| Philip D. Anker | M | - |
University of Pennsylvania
| 4 years |
| Gretchen L. Temeles | M | - |
University of Pennsylvania
| 4 years |
| Harry L. Alverson | M | - |
University of Pennsylvania
| 2 years |
| Daniel A. David | M | - |
University of Pennsylvania
| 4 years |
| Bernard Lee | M | - |
University of Pennsylvania
| 3 years |
| Andrew Baum | M | - |
University of Pennsylvania
| 4 years |
| Whittemore Kim | F | - |
University of Pennsylvania
| 4 years |
| Larry Attanasio | M | - |
University of Pennsylvania
| 4 years |
| David L. Felten | M | - |
University of Pennsylvania
| 3 years |
| Stephen Lioce | M | - |
University of Pennsylvania
| 2 years |
| Merrie Frankel | F | 69 |
University of Pennsylvania
| 4 years |
| Benjamin Ginsberg | M | - |
University of Pennsylvania
| 4 years |
| Kira Sterling | F | - |
University of Pennsylvania
| 4 years |
| Corinne Mundin | F | - |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 3 years |
| Brian Sullivan | M | - |
University of Pennsylvania
| 1 years |
| David John Pollitzer | M | - |
University of Pennsylvania
| 4 years |
| Gordon Todd Halliday | M | - |
University of Pennsylvania
| 4 years |
| Eduardo Soriano | M | 69 |
University of Pennsylvania
| 4 years |
| Lars Welin | M | 83 |
University of Pennsylvania
| 2 years |
| Chia Ching Woo | F | 67 |
University of Pennsylvania
| 4 years |
| Robert Beer | M | - |
University of Pennsylvania
| 4 years |
| William H. Bohnett | M | - |
University of Pennsylvania
| 3 years |
| Joel Michael Shaps | M | - |
University of Pennsylvania
| 4 years |
| Stephen G. Kozey | M | - |
University of Pennsylvania
| 3 years |
| Jim W. Rappaport | M | - |
University of Pennsylvania
| 4 years |
| Todd M. Schefler | M | 67 |
University of Pennsylvania
| 4 years |
| Walter T. Bromfield | M | 68 |
University of Pennsylvania
| 4 years |
| David D. Elliman | M | 73 |
University of Pennsylvania
| 4 years |
| Wayne H. Shaner | M | - |
University of Pennsylvania
| 2 years |
| Wayne Weisman | M | 68 |
University of Pennsylvania
| 4 years |
| David J. Steirman | M | - |
University of Pennsylvania
| 4 years |
| Frank J. Husic | M | - |
University of Pennsylvania
| 1 years |
| Marc Grodman | M | 72 |
University of Pennsylvania
| 4 years |
| Irwin Allan Michael | M | - |
University of Pennsylvania
| 2 years |
| Mitchell Quain | M | 73 |
University of Pennsylvania
| 4 years |
| Vartan Gregorian | M | 90 |
University of Pennsylvania
| - |
| Dennis Berman | M | 73 |
University of Pennsylvania
| 4 years |
| David M. Petrick | M | 73 |
University of Pennsylvania
| 3 years |
| Marc P. Applebaum | M | - |
University of Pennsylvania
| 4 years |
| Davis Stowell | M | 71 |
University of Pennsylvania
| 8 years |
| Michael R. Granito | M | 71 |
University of Pennsylvania
| 4 years |
| Herbert Anderson Denton | M | 77 |
University of Pennsylvania
| 2 years |
| Edmond Villani | M | 77 |
University of Pennsylvania
| 3 years |
| Mark Simon Fife | M | - |
University of Pennsylvania
| 4 years |
| Herald L. Ritch | M | - |
University of Pennsylvania
| 2 years |
| Steven J. Winick | M | - |
University of Pennsylvania
| 4 years |
| Stephan Ladisch | M | - |
University of Pennsylvania
| 4 years |
| John W. Potter | M | - |
University of Pennsylvania
| 2 years |
| Jim E. Daverman | M | - |
University of Pennsylvania
| 2 years |
| Bryant K. Berg | M | - |
University of Pennsylvania
| 4 years |
| Terry M. Finn | M | - |
University of Pennsylvania
| 3 years |
| Dorothy Puhy | F | 71 |
University of Pennsylvania
| 4 years |
| Michael D. Schneider | M | - |
University of Pennsylvania
| 3 years |
| Bhartan R. Patel | M | 75 |
University of Pennsylvania
| 3 years |
| Carl A. Schulz | M | - |
University of Pennsylvania
| 4 years |
| Lloyd Buchanan | M | - |
University of Pennsylvania
| 4 years |
| Angus Chisholm Littlejohn | M | - |
University of Pennsylvania
| 4 years |
| Jay David Namyet | M | - |
University of Pennsylvania
| 4 years |
| Howard Gellis | M | - |
University of Pennsylvania
| 3 years |
| Andrew R. Brownstein | M | - |
University of Pennsylvania
| 2 years |
| Gary A. Shangold | M | 71 |
University of Pennsylvania
| 4 years |
| Roy Shiller Neff | M | 71 |
University of Pennsylvania
| 2 years |
| Ken Leech | M | - |
University of Pennsylvania
| 6 years |
| Robert Clarke | M | - |
University of Pennsylvania
| 4 years |
| Peter Ginsberg | M | 70 |
University of Pennsylvania
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Barry Frankel
- Personal Network
